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also calculated. All costs were inflated to 2010 US$. RESULTS: Data were available
for 900 employees (HCV-Tx216;HCV-noTx684). The cohorts differed in salaries,
the %married, %white, and %exempt. Mean HCV-noTx cohort IN ($836,P0.0001)
and OUT ($488,P0.0018) costs were higher, and HCV-Tx MD ($564, P0.0001), LAB
($42,P0.0001) and Rx ($21,420,P0.0001) costs were higher. The HCV-noTx cohort
had more IN services (1.83, P0.0021), while the HCV-Tx cohort had more MD
(15.48,P0.0001), LAB (3.31,P0.0001) and Rx (12.0,P0.0001) services. Overall,
HCV-Tx direct medical costs were $3556 (services54.40) which were lower than
the HCV-noTx ($4234;services35.39). The HCV-Tx cohort had 27.84 Rxs ($22,726)
vs the HCV-noTx cohort’s 15.84 Rxs ($1408). CONCLUSIONS: Higher costs associ-
ated with HCV Treatment in the MD office offset IN and OUT costs.
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OBJECTIVES: To determine if subsets of gastroesophageal reflux disease (GERD)
patients vary with respect to healthcare utilization.METHODS: This retrospective
analysis identified commercial enrollees 18-75 years oldwith claims for GERD (ICD-
9-CM: 530.81 or 530.11) and proton pump inhibitors (PPI) during 01/01/05 – 06/30/09.
Patients were further required to have no claims for HIV, pregnancy, inflammatory
bowel disease or cancer at any time, or GERD prescription or gastric/duodenal ulcer
prior to initial GERD diagnosis. Eligible patients were then stratified based onmed-
ical claims for other symptoms during a 12 month period centered on their first
GERD diagnosis: Stage A (GERD diagnosis, no other symptoms); Stage B (GERD 
respiratory symptoms); Stage C (GERD  Barrett’s esophagus); Stage D (GERD 
esophageal stricture); Stage E (GERD  iron deficiency anemia or acute hemor-
rhage). The stages were compared with respect to GERD treatment, other gastro-
intestinal symptoms and GERD-related or all-cause costs for outpatient, inpatient,
and pharmacy care during the first six months after initial diagnosis using univar-
iate statistics.RESULTS: 174,597 patientswere analyzed: StageA: 74%, Stage B: 20%,
Stage C: 1%, Stage D: 2%, Stage E: 3%. Versus stages A and B, patients in Stages C-E
were more likely to visit a gastroenterologist (53.9% vs. 12.9%), receive multiple PPI
(11.5% vs. 7.4%) and had higher rates of gastritis/duodenitis (17.0% vs. 5.9%), esoph-
ageal ulcers (4.4% vs. 0.3%), and esophageal surgery (7.6% vs. 0.3%). Six month
GERD-related costs ranged from $615/patient (Stage A) to $1,714/patient (Stage D);
all-cause costs ranged from $4,195/patient (Stage A) to $11,340/patient (Stage E)
(p0.0001 for all contrasts). CONCLUSIONS: While GERD patients with additional
complications represented a relatively small portion of the total sample, their signif-
icantly higher costs and events suggest an opportunity for improving patient care.
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OBJECTIVES: To systematically review literature on the burden of illness in pa-
tients with CC and IBS subtypes.METHODS:Medline, Medline In-process, EconLit,
CINAHL, Cochrane Library, and AGA abstracts were searched. Studies reporting
economic and quality of life (QOL) outcomes in IBS or CC patients were included.
Study designs included case control, observational studies, surveys, and retrospec-
tive analyses. RCT and studies reporting outcomes attributable to a specific therapy
were excluded. RESULTS: 882 unique studies were identified and 35 selected: 16
evaluated economicmeasures only, 16 humanisticmeasures only, and 3 economic
and humanistic measures. Studies were excluded if patient populations or out-
comes were not relevant. Selected studies included a total of 63,816 patients: 1,706
IBS-C, 2,264 IBS-D, 2,892 IBS-A, 15,830 IBS sub-type unspecified, and 1,278 CC pa-
tients. Nineteen studies assessed economic measures: 11 evaluated direct costs, 1
indirect costs, and 7 direct and indirect costs. Indirect costs generally reflected
estimated work productivity loss due to IBS symptoms or healthcare-seeking be-
havior. US-based estimates of direct costs per IBS patient were $1,562/year (2002
USD) to $7,547/year (year NR, published in 2000); direct costs per CC patient were
$1,912/year (2002USD) to $7,522/year (2002-2003USD). Indirect per IBS patient costs
ranged from $791/year (1998 USD) to $7,737/year (year NR, published 2005). No
study assessed costs associated with IBS-C/D/A subtypes. In studies comparing IBS
patients to non-IBS controls, IBS patients had significantly lower SF-36 domain scores,
notably in vitality, general health, and physical functioning. CONCLUSIONS: Our re-
search identified a range ofmethods and estimates of the burden of IBS and CC. No
economic study reported recent cost estimates by IBS subtypes; only two estimated
direct costs of CC. No studies presented QOL information in CC patients; however,
patients suffering from IBS hadmeasurable burden of disease based onQOL scores.
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OBJECTIVES: In Canada, adalimumab and infliximab are approved for the treat-
ment of moderate to severe active Crohn’s disease (CD). Product monographs sug-
gest that the dose may be increased in case of incomplete response. The objective
of this study was to analyze, in a real world setting, dose variations in CD patients
who initiated adalimumab or infliximab treatment. METHODS: A retrospective
cohort study was conducted using data from the Regie de l’assurance maladie du
Quebec (RAMQ) for a random sample of patients with a CD diagnosis, who had
initiated adalimumab or infliximab between February 2008 andDecember 2008. For
adalimumab, dose increase was considered when the dose received exceeded
40mg every otherweek over at least an 8-week period. For infliximab, dose increase
was considered either when the dose was increased or interval between doses was
reduced for two periods of 8 weeks after the third injection. RESULTS: The cohort
included a total of 290 patients of which 135 patients were initiatedwith infliximab
and 155 with adalimumab. The mean age was 42.2 years (SD16.9). After 12
months, 14.2%(22/155) of patients with adalimumab and 22.2%(30/135) of patients
with infliximab had experienced a dose increase (p0.05). Average medication
costs in the year following initiation of adalimumab or infliximab, for patients who
did not adjust doses were CAD$10,250 and CAD$14,957, respectively (p0.01). For
patients who experienced a dose increase or reduced interval between doses, av-
erage medication costs were CAD$19,789 with adalimumab and CAD$25,550 with
infliximab (p0.013). CONCLUSIONS: CD patients treated with infliximab had a
significantly higher rate of dose increases compared with patients treated with
adalimumab. Results of this RAMQdatabase analysis illustrate that, in a real-world
setting, dose increase or reduction of interval between doses are associated with
increased treatment costs. In both recommended and adjusted dosing, adali-
mumab demonstrated significant cost savings over infliximab.
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OBJECTIVES: To assess the economic value of treating CHB patients with Entecavir
relative to the current situation in Russiawith no treatment.METHODS:Wecarried
out the Perceived Value Assessment (PVA) of Entecavir (937 patients) vs. no treat-
ment (971 patients) using amultilayeredMarkovianmodel (disease state transition
model: F0/F1 – F2/F3/F4 (Fibrosis) –F4 (Advanced Fibrosis/Cirrhosis) – Decompen-
sated Cirrhosis – Hepatocellular Carcinoma – Liver Transplant – Post Liver Trans-
plant), developed by J.Wells fromMonitor Group. It is consistentwith a cost-benefit
analysis, where the clinical benefits of treatment with ETV (occurrence of histolog-
ical improvement and CHB disease regression, avoidance of renal adverse events,
avoidance of additional monitoring requirements) are expressed in monetary
terms (Rubles). Costs of treating a chronic Hepatitis B patient per day avoided by 5
years of Entecavir treatment and 25 years of follow up (total 30 years) can be
considered as benefits of treating. RESULTS: As patients progress into more ad-
vanced disease states their treatment becomes disproportionately more expen-
sive: 420.7 USD for F0/F1, 1 935.2 USD for F2/F3/F4, 2 515.6 USD forF4, 10 947.1 USD
for Decompensated Cirrhosis, 4 549.9 USD for Hepatocellular Carcinoma, 10 092
USD for Liver Transplant, 49 613.6 USD for Post Liver Transplant. Costs of treating
a CHB patient avoided by 5 years of Entecavir treatment and 25 years of follow up –
30.3 USD per day: 4.8 USD per day for F0/F1, F2/F3/F4 and F4; 3.2 USD per day for
Decompensated Cirrhosis; 0.6 USD per day for Hepatocellular Carcinoma; 0.45 USD
per day for Liver Transplant; 21.25 USD per day for Post Liver Transplant. Cost of
Entecavir treatment is 8.8 USD per day (29.1 % of total costs avoided per patient per
day of Entecavir treatment). CONCLUSIONS: Entecavir represents a true “spend to
save” strategy: cost of therapy is fully outweighed by the economic benefits of
treatment.
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OBJECTIVES:Chronic hepatitis B (CHB) can lead to progressive liver disease, including
cirrhosis, hepatocellular carcinoma and death. New options for long-term antiviral
treatment decrease financial burden of CHB to the healthcare system and require
physicians, payers and healthcare decision-makers to evaluate its economic value.To
assess the economic value of treatment with Entecavir relative to treatment with
Tenofovir in the Russian healthcare system.METHODS:We carried out the Perceived
Value Assessment (PVA) of Entecavir (ETV) vs. Tenofovir (TFV) using multilayered
Markovian model (disease state transition model: F0/F1 – F2/F3/F4 (Fibrosis) – F4
(Advanced Fibrosis/Cirrhosis) – DecompensatedCirrhosis –Hepatocellular Carcinoma
– Liver Transplant – Post Liver Transplant), developed by J.Wells fromMonitor Group.
In termsof PVAmodelweevaluated thecomparativevalueprovided to thehealth care
systembyEntecavir versusTenofovir treatment (total of 30 yearsmodeled) depending
on duration of treatment and the follow-up period. The primary outcomemeasure of
the model is the “Per pill Cost”. RESULTS: As patients progress into more advanced
disease states their treatment becomesdisproportionatelymore expensive: 420.7USD
for F0/F1, 1 935.2 USD for F2/F3/F4, 2 515.6 USD for F4, 10 947.1 USD for Decompen-
sated Cirrhosis, 4 549.9 USD forHepatocellular Carcinoma, 10 092USD for Liver Trans-
plant, 49 613.6USD for Post LiverTransplant. ETV’sprice is only 0.11 greater thanTFV’s
price. Value gapbetweenETVandTFV for 5 years of therapywith 25 years of follow-up
period was 4.8 USD per pill. It was determined by the long-term efficacy of ETV.
CONCLUSIONS: PVA Cost benefit simulation with 30 year time horizon and maxi-
mum treatment duration of 5 years demonstrated ETV’s economic valuewas 4.8 USD
greater than that of TFV.
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